ADVM Adverum Biotechnologies, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

ADVM [NASD]

Adverum Biotechnologies, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.09	Insider Own	0.50%	Shs Outstand	73.80M	Perf Week	-0.76%
Market Cap	1.64B	Forward P/E	-	EPS next Y	-1.28	Insider Trans	-27.10%	Shs Float	77.29M	Perf Month	51.93%
Income	-72.90M	PEG	-	EPS next Q	-0.28	Inst Own	80.01%	Short Float	14.72%	Perf Quarter	59.60%
Sales	0.30M	P/S	5477.14	EPS this Y	15.00%	Inst Trans	38.01%	Short Ratio	7.86	Perf Half Y	96.14%
Book/sh	4.12	P/B	5.06	EPS next Y	-4.50%	ROA	-29.60%	Target Price	17.14	Perf Year	87.76%
Cash/sh	3.77	P/C	5.53	EPS next 5Y	-	ROE	-35.50%	52W Range	4.96 - 23.79	Perf YTD	81.08%
Dividend	-	P/FCF	-	EPS past 5Y	16.40%	ROI	-39.20%	52W High	-12.32%	Beta	2.30
Dividend %	-	Quick Ratio	17.90	Sales past 5Y	-15.30%	Gross Margin	-	52W Low	320.56%	ATR	1.85
Employees	114	Current Ratio	17.90	Sales Q/Q	-100.00%	Oper. Margin	-	RSI (14)	67.49	Volatility	10.81% 10.67%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-35.20%	Profit Margin	-	Rel Volume	0.38	Prev Close	21.12
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 28 AMC	Payout	-	Avg Volume	1.45M	Price	20.86
Recom	2.10	SMA20	6.27%	SMA50	41.76%	SMA200	87.25%	Volume	546,096	Change	-1.23%

May-13-20

Initiated

RBC Capital Mkts

Outperform

$24

May-05-20

Upgrade

SunTrust

Hold → Buy

$13 → $21

Apr-28-20

Initiated

Goldman

Buy

$17

Mar-16-20

Initiated

SVB Leerink

Outperform

$17

Feb-10-20

Upgrade

Chardan Capital Markets

Neutral → Buy

$20

Feb-10-20

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$8 → $21

Oct-15-19

Reiterated

Chardan Capital Markets

Neutral

$6 → $10

Sep-13-19

Reiterated

Chardan Capital Markets

Neutral

$10 → $6

Jun-14-19

Resumed

Raymond James

Mkt Perform

Nov-02-18

Downgrade

SunTrust

Buy → Hold

Nov-02-18

Downgrade

Raymond James

Outperform → Mkt Perform

Sep-21-18

Initiated

Cantor Fitzgerald

Overweight

Aug-30-18

Initiated

SunTrust

Buy

$11

Feb-15-18

Resumed

Piper Jaffray

Overweight

$12

Oct-12-17

Initiated

Raymond James

Outperform

May-29-20 11:30AM	Adverum Biotechnologies, Inc. (ADVM) Q1 2020 Earnings Call Transcript Motley Fool
May-28-20 05:45PM	Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results GlobeNewswire
02:30PM	Adverum Biotechnologies, Inc. to Host Earnings Call ACCESSWIRE
May-25-20 11:30AM	Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? Zacks
May-21-20 04:05PM	Adverum Biotechnologies to Host a Conference Call and Webcast to Report First Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
May-09-20 08:00AM	3 Best Healthcare Stocks to Buy in May Motley Fool
May-07-20 11:30AM	Is Adverum Biotechnologies (ADVM) Outperforming Other Medical Stocks This Year? Zacks
May-06-20 12:53PM	Here's Why Adverum Biotechnologies Is Soaring Today Motley Fool +7.66%
May-05-20 04:11PM	Small Biotech Rockets To 5-Year High On Regeneron-Rivaling Gene Therapy Investor's Business Daily +38.35%
10:42AM	Why Adverum Biotechnologies Stock Is Soaring Today Motley Fool
08:00AM	The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout Benzinga
May-04-20 05:10PM	Adverum Biotechnologies Reports Positive Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD GlobeNewswire +14.42%
08:20AM	Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30% (NEWS-PORTAL) TipRanks
May-03-20 07:00AM	Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30% TipRanks
Apr-30-20 04:05PM	Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO GlobeNewswire -9.26%
Apr-28-20 12:00PM	Here's Why Momentum Investors Will Love Adverum Biotechnologies (ADVM) Zacks
12:00PM	All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy Zacks
Apr-27-20 04:01PM	Adverum Biotechnologies to Host a Conference Call and Webcast to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD GlobeNewswire
08:00AM	Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD GlobeNewswire
Apr-20-20 04:05PM	Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors GlobeNewswire +8.91%
Apr-01-20 01:42AM	Edited Transcript of ADVM earnings conference call or presentation 12-Mar-20 8:30pm GMT Thomson Reuters StreetEvents -10.54%
Mar-26-20 08:55AM	Adverum (ADVM): Strong Industry, Solid Earnings Estimate Revisions Zacks +9.21%
Mar-18-20 12:00PM	What Makes Adverum Biotechnologies (ADVM) a New Buy Stock Zacks -5.82%
Mar-16-20 06:06AM	Adverum Biotechnologies, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St. -13.17%
Mar-12-20 05:55PM	Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates Zacks -13.82%
04:01PM	Adverum Biotechnologies Reports Recent Business Progress and Fourth Quarter 2019 Financial Results GlobeNewswire
02:30PM	Adverum Biotechnologies, Inc. to Host Earnings Call ACCESSWIRE
Mar-11-20 04:38PM	Adverum Biotechnologies Announces Data Presentations at ARVO 2020 GlobeNewswire -9.30%
09:46AM	Why Earnings Season Could Be Great for Adverum (ADVM) Zacks
Mar-05-20 04:01PM	Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
Mar-04-20 04:25PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. ADVM GlobeNewswire
Mar-03-20 02:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM ACCESSWIRE
10:29AM	ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc. and Encourages Investors to Contact the Firm ACCESSWIRE
Mar-02-20 05:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM PR Newswire +6.74%
Feb-26-20 06:50PM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:00PM	ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc. PR Newswire
12:30PM	Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline Zacks
09:30AM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
Feb-25-20 03:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM ACCESSWIRE
12:26PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:00AM	ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc. GlobeNewswire
08:00AM	Adverum Biotechnologies Appoints Angela Thedinga as Chief Technology Officer GlobeNewswire
Feb-24-20 05:31PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM GlobeNewswire -7.34%
05:10PM	ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc. ACCESSWIRE
Feb-19-20 04:01PM	Adverum Biotechnologies to Present at Upcoming Investor Conferences GlobeNewswire
Feb-17-20 10:06AM	3 Stocks That Are Way More Expensive Than Tesla GuruFocus.com
05:34AM	Trade Alert: The Independent Director Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), James Scopa, Has Just Spent US$138k Buying Shares Simply Wall St.
Feb-15-20 10:09AM	Adverum (ADVM) Alert: Johnson Fistel Launches Investigation into Adverum Biotechnologies; Investors Encouraged to Contact Firm PR Newswire
Feb-14-20 04:01PM	Adverum Biotechnologies Announces Closing of $150 Million Public Offering of Common Stock GlobeNewswire
Feb-11-20 08:27PM	Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock GlobeNewswire +19.13%
Feb-10-20 04:01PM	Adverum Biotechnologies Announces $100 Million Public Offering of Common Stock GlobeNewswire +17.68%
Feb-08-20 03:06PM	Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020 GlobeNewswire
Feb-02-20 01:04PM	The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus Benzinga
Jan-31-20 06:40AM	We're Not Very Worried About Adverum Biotechnologies's (NASDAQ:ADVM) Cash Burn Rate Simply Wall St. -5.00%
Jan-28-20 04:02PM	Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2020 Meeting GlobeNewswire
Jan-27-20 04:00PM	Adverum Biotechnologies Moves to New Headquarters and Expands Laboratory Space in Redwood City, CA GlobeNewswire
09:17AM	The Market Timing Secrets No One Talks About - January 27, 2020 Zacks
Jan-12-20 06:00PM	Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook GlobeNewswire
Jan-07-20 10:00AM	Simple Market Timing Strategies That Work - January 07, 2020 Zacks
Dec-18-19 04:01PM	Adverum Biotechnologies to Present at Upcoming Conferences GlobeNewswire
Dec-14-19 08:41PM	Hedge Funds Dropped The Ball On Adverum Biotechnologies, Inc. (ADVM) Insider Monkey
Dec-02-19 10:53AM	Shareholder Alert - Adverum Biotechnologies - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM GlobeNewswire
07:28AM	Announcing: Adverum Biotechnologies (NASDAQ:ADVM) Stock Increased An Energizing 264% In The Last Three Years Simply Wall St.
Nov-25-19 08:56AM	Timing the Market, Is it Possible? - November 25, 2019 Zacks +5.68%
Nov-20-19 04:01PM	Adverum Biotechnologies to Participate in Piper Jaffrays 31st Annual Healthcare Conference GlobeNewswire
Nov-11-19 10:50AM	Adverum Biotechnologies Shareholder Alert Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM GlobeNewswire
Nov-08-19 05:07PM	Edited Transcript of ADVM earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents +7.06%
Nov-07-19 07:15PM	Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM	Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2019 Financial Results GlobeNewswire
Nov-04-19 08:44AM	When Does Market Timing Actually Work? - November 04, 2019 Zacks
Oct-31-19 04:01PM	Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates GlobeNewswire +5.67%
Oct-30-19 04:01PM	Adverum Biotechnologies Expands Leadership Team with the Appointment of Peter Soparkar as Chief Legal Officer GlobeNewswire
Oct-29-19 12:37PM	Adverum Biotechnologies, Inc. (ADVM): Hedge Funds Getting Back In? Insider Monkey
Oct-24-19 08:00AM	Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD GlobeNewswire
Oct-23-19 08:00AM	Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress GlobeNewswire
Oct-14-19 08:36AM	The Market Timing Secrets No One Talks About - October 14, 2019 Zacks +15.12%
Oct-11-19 07:26PM	Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting GlobeNewswire
08:14AM	The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Sep-30-19 09:04AM	Adverum Biotechnologies Enters Oversold Territory Zacks
Sep-26-19 05:25PM	Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting GlobeNewswire
Sep-25-19 09:00AM	Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why Zacks
Sep-24-19 09:04AM	The Keys to Successfully Timing the Markets - September 24, 2019 Zacks
Sep-19-19 06:34AM	Should You Take Comfort From Insider Transactions At Adverum Biotechnologies, Inc. (NASDAQ:ADVM)? Simply Wall St.
Sep-13-19 12:29PM	A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019 Benzinga
10:06AM	Adverum Reports Data From Phase I Wet AMD Study, Stock Down Zacks
Sep-12-19 11:30AM	Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial Benzinga -50.33%
07:38AM	The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study Benzinga
02:41AM	Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD GlobeNewswire
Sep-04-19 04:01PM	Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting GlobeNewswire +9.24%
08:58AM	The Keys to Successfully Timing the Markets - September 04, 2019 Zacks
Aug-28-19 04:01PM	Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October GlobeNewswire
Aug-27-19 11:36AM	Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock? Zacks
Aug-16-19 11:23AM	What's in Store for Aytu BioScience's (AYTU) Q4 Earnings? Zacks +7.46%
Aug-15-19 08:45PM	Edited Transcript of ADVM earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
09:57AM	The Keys to Successful Timing the Markets - August 15, 2019 Zacks
Aug-09-19 08:49PM	Adverum Biotechnologies, Inc. (ADVM) Q2 2019 Earnings Call Transcript Motley Fool -6.17%
Aug-08-19 05:15PM	Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates Zacks +5.21%
04:00PM	Adverum Biotechnologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-06-19 09:54AM	What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks +6.86%

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration and diabetic retinopathy; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five ophthalmic indications; Regeneron Pharmaceuticals, Inc.; and GenSight Biologics S.A. to develop gene therapy products to deliver certain therapeutic transgenes. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gasmi Mehdi	Director	May 21	Option Exercise	4.80	3,599	17,275	278,041	May 22 06:55 PM
Gasmi Mehdi	Director	May 20	Option Exercise	4.80	1,401	6,725	275,843	May 22 06:55 PM
Gasmi Mehdi	Director	May 20	Sale	20.01	1,401	28,030	274,442	May 22 06:55 PM
Gasmi Mehdi	Director	May 18	Option Exercise	4.80	5,000	24,000	279,442	May 20 07:34 PM
Gasmi Mehdi	Director	May 18	Sale	18.17	5,000	90,833	274,442	May 20 07:34 PM
Gasmi Mehdi	Director	May 06	Option Exercise	4.80	25,000	120,000	299,442	May 20 07:34 PM
PATTERSON LEONE D	CEO, President and Director	May 06	Option Exercise	3.44	20,000	68,800	143,659	May 08 06:25 PM
PATTERSON LEONE D	CEO, President and Director	May 06	Sale	20.02	20,000	400,400	123,659	May 08 06:25 PM
Gasmi Mehdi	Director	May 06	Sale	20.03	25,000	500,668	274,442	May 20 07:34 PM
Gasmi Mehdi	Director	May 05	Option Exercise	4.80	10,000	48,000	284,442	May 20 07:34 PM
Gasmi Mehdi	Director	May 05	Sale	16.26	10,000	162,573	274,442	May 20 07:34 PM
Scopa James Paul	Director	May 04	Option Exercise	6.48	23,334	151,204	53,334	May 05 06:44 PM
PATTERSON LEONE D	CEO, President and Director	Mar 20	Option Exercise	3.44	24,424	84,019	162,955	Mar 25 05:28 PM
PATTERSON LEONE D	CEO, President and Director	Mar 20	Sale	10.17	39,526	401,908	123,429	Mar 25 05:28 PM
PATTERSON LEONE D	CEO, President and Director	Mar 17	Sale	10.02	474	4,749	138,531	Mar 18 07:33 PM
Gasmi Mehdi	Director	Feb 18	Option Exercise	4.80	5,000	24,000	263,979	Feb 20 04:51 PM
Gasmi Mehdi	Director	Feb 18	Sale	16.23	5,000	81,156	258,979	Feb 20 04:51 PM
Scopa James Paul	Director	Feb 14	Buy	13.75	10,000	137,500	30,000	Feb 14 08:58 PM
Gasmi Mehdi	Director	Feb 12	Option Exercise	4.80	10,000	48,000	268,979	Feb 14 08:57 PM
Gasmi Mehdi	Director	Feb 12	Sale	15.07	10,000	150,690	258,979	Feb 14 08:57 PM
PATTERSON LEONE D	CEO, President and Director	Dec 23	Sale	10.72	40,000	428,800	228,496	Dec 26 04:47 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience